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Abstract 
 
Background and aims: Prescribing medicines in an off-label manner for children with chronic 
conditions is sparsely documented, even more so among developing countries. This needs 
addressing. The objective was to investigate the extent of this prescribing among children with 
epilepsy, asthma, and sickle cell anaemia in Nigeria. Methods: 3UHVFULSWLRQVIRUFKLOGUHQ\HDUV
documented in their case files that attended paediatric clinics in Lagos, Nigeria, for these three 
conditions between January and October 2015, were reviewed retrospectively to extract data on the 
medicines prescribed. British National Formulary for children and American Hospital Formulary 
Service Drug information were used as references.  Results: 477 patients received 1746 
prescriptions. Off-label prescriptions were seen in 7.7% of prescriptions, related to dose (93; 68.9%), 
indication (22; 16.3%), and age (20; 14.8%). Nervous system (525; 30.1%) and anti-infective (441; 
25.2%) medicines were the most prescribed but only 9.5% and 8.2% of the respective prescriptions 
were off-label. Children with epilepsy received the most number (94; 69.6%) of off-label prescriptions. 
The three chronic conditions did not associate significantly with the category of off-label medicine 
prescribed (p= 0.925). Conclusion: Off-label prescribing for children with epilepsy, asthma and sickle 
cell anaemia occurs. Encouragingly, the overall rate appears low in Nigeria. 
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1. Introduction 
Prescribing in an off-label manner refers to unlabelled or unapproved prescribing [1]. It involves the 
prescribing of a registered medicine for a use that is not included or claimed in the summary of 
product characteristics (SPC). This includes prescribing for a different indication(s); or in a non-
recommended age-group; or dose or dosing regimens that are different from recommended dosing 
regimens; or via a different route, or in a different dosage form [2]. The off-label use of medicines, 
however, differs from the use of unregistered or unlicensed medicines; yet they have been considered 
as a single entity in previous studies [3-5]. Unregistered medicines are medicines that have not been 
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assessed or approved by a competent regulatory authority such as the US Food and Drug 
Administration, the European Medicines Agency (EMA) [2], the Pharmaceuticals and Medical Devices 
Agency of Japan [6], or the National Agency for Food and Drug Administration and Control (NAFDAC) 
in Nigeria [7]. On the other hand, unlicensed medicines are, for example, those prepared 
extemporaneously DQG³VSHFLDOV´ZKLFKDUHQRWVXEMHFWHGWRWKHVDPHULJRURXVTXDOLW\FKHFNVDV
registered/licensed medicines and/or do not have marketing authorisation in the country in which they 
are used [8].  
 
Globally, there are few studies on medicine utilisation and safety in children [9, 10]. Data regarding 
the off-label medicine use in children are few from resource limited countries, particularly sub-
Saharan African countries [11, 12]. In spite of the problems of off-label use of medicine, off-label 
prescribing is not illegal and may well be correct [2]. It may well be necessary and appropriate in 
some circumstances where there are no therapeutic alternatives. Moreover, off-label prescribing is 
acceptable in situations where the likely benefits of the considered medicine outweighs the potential 
risks. However, there are concerns about the safety, economic costs, and potentially ethical issues 
involved with such prescribing [2]. The off-label use of medicines is common in children because only 
a few clinical trials have been conducted to evaluate new medicines in paediatric population due to 
their vulnerability as well as ethical challenges [13]. Furthermore, major clinically significant 
medicines, as well as essential medicines, frequently used for adults are neither tested nor officially 
approved for use in children. For example, paracetamol administration to a premature infant as an off-
label medicine for age and weight, intranasal administration of adrenaline rather than intravenous 
route, and the use as an analgesic of morphine without pediatric information or codeine without 
pediatric data constitute off-label medicine use [14]. Off-label prescribing of medicines for children 
predisposes them to medication errors since dose calculations must be individualized for each child, 
especially in the absence of appropriate dosing information from the pharmaceutical manufacturer.  
Off-label use of medicines for children is typically less evaluated than on-label use; consequently, off-
label use of medicines may be associated with an increase in medication errors [15]. Previous studies 
have reported that medication errors are three times more common in pediatric than adult patients 
[16, 17]. Another study evaluating pediatric antidepressant drug use in a national error-reporting 
database reported that 77% of the errors involved off-label prescribing [15]. A few studies have 
analysed the risk of potential adverse reactions associated with off-label use of medicines [18-22]. In 
two prospective studies, the incidence of adverse reactions was higher among children treated with 
medicines used for unapproved indications or used off-label compared to those treated with 
medicines for approved indications or used on-label [18, 19]. Three other studies involving 
spontaneous adverse drug reaction (ADR) reporting showed that off-label medicine use, including 
other incorrect uses, was more often associated with ADRs than those used according to the when 
product labelling [20-22]. 
 
Prescribing medicines in an off-label manner is high globally and occurs more frequently in children, 
with neonates, children in intensive care or the critically ill being the most exposed [23]. The 
prevalence of off-label prescriptions among paediatric population varies from country to country, and 
is influenced by factors such as disease patterns, age-group, settings, and type of analysis conducted 
[11, 24, 25]. A prevalence of 9% was reported among paediatric outpatients in the Czech Republic; 
whilst higher rates were reported in Germany where parents of all non-institutionalised children and 
adolescents were interviewed regarding off-label medicine use among their children [24, 25]. Among 
children under-five in South western Nigeria, a prevalence of 21.5% has been reported [12], whilst 
70% was reported among hospitalised children in India [11]. Finally, a pan-European study showed 
off-label and unlicensed medicine use to be as high as 90 % in preterm neonates [26].   
Epilepsy, asthma, and sickle cell anaemia are common childhood chronic illnesses with high 
prevalence rates in Nigeria [27]. There is no information in the public domain on the medicines 
approved by the NAFDAC for controlling epileptic seizures, asthmatic attack, and vaso-occlusive 
crisis in sickle cell anemic children. However, only a few medicines for each of these conditions are 
included in the national essential medicines list [28].  Included in the list are carbamazepine, 
diazepam, ethosuximide, paraldehyde, phenobarbital, phenytoin, and sodium valproate for seizure 
control in epilepsy. Aminophylline, beclomethasone disproportionate, ipratropium bromide, and 
salbutamol are the only anti-asthmatic medicines listed in the essential medicines list. Unfortunately 
hydroxyurea, that is widely used in developed countries to control vaso-occlusion in sickle cell 
anaemia, is conspicuously omitted in the National essential medicines list.   
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Epilepsy, asthma, and sickle cell anaemia are often associated with various comorbidities. The most 
frequently reported asthma comorbid conditions are rhinitis, sinusitis, gastroesophageal reflux 
disease, obstructive sleep apnea, hormonal disorders and psychopathologies [29]. Comorbid 
conditions in epilepsy range from psychiatric disorders, cognitive disorders, migraine, and sleep 
disorders, behavioural problems to sudden unexpected death in epilepsy (particularly in individuals 
with poorly controlled seizures) [30]. Depression, anxiety, stress due to vaso-occlusive crisis, and 
recurrent bacteria and malaria infections are notable comorbidities in children with sickle cell anemia 
[31, 32]. These various complications are often treated with medications different from those that are 
specifically used to control the acute state of the chronic illnesses or any concurrent illness. 
Consequently, off-label medicine use is likely to be greater in children with epilepsy, asthma and 
sickle cell anaemia, and those with other chronic conditions requiring complex medications, compared 
to other acutely-ill children. 
 
Studies evaluating the use of medicines in an off-label manner in children with epilepsy and asthma 
are few, whilst none appear to exist for children with sickle cell anaemia [33-35]. The majority of the 
published studies have focused on the specific medicines for controlling the acute state of the chronic 
illnesses [33], are limited to specific paediatric age groups [35], or included both unlicensed and off-
label medicines [34].  We sought to address this lack of published studies especially for developing 
countries. In this study, we investigated the patterns of medicines prescribed in an off-label manner 
for children with epilepsy, asthma, and sickle cell anaemia attending a paediatric specialty clinic in 
Nigeria. Unlike previous studies, concomitant medicines used to treat comorbidities that are 
associated with the chronic illnesses and those frequently used for controlling the acute state of the 
chronic illnesses were evaluated.  
 
2. Methods  
 
2.1 Setting and participants 
This study was carried out at the Lagos University Teaching Hospital (LUTH), Lagos State, Nigeria. 
LUTH is a 771-bed tertiary hospital providing specialty services in all aspect of medical care [34].  
Children with epilepsy, asthma and sickle cell anaemia attending specialty paediateric clinics were 
included and classified into five age groups: SUHWHUPQHZERUQLQIDQWVGHOLYHUHGDWZHHNV
gestation), term newborn infants (0-27 days), infants and toddlers (128 days to 23 months), children 
(2-11 years), and adolescents (12-16 years) according to the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 
Harmonised Tripartite Guideline E11 for clinical investigation of medicinal products in the paediatric 
population [37]. 
 
2.2 Design 
Retrospective descriptive study involving the review of case files of children with epilepsy, asthma and 
sickle cell anaemia. The case files of previously hospitalised or outpatients attending the three 
specialty clinics between January and October 2015 were reviewed, as this is the peak period for 
presentation based on a review of paediatric medical records for five consecutive years (2011 to 
2015). Criteria for inclusion were patients aged 0-16 years prescribed a minimum of one enteral (oral) 
medicine during admission or clinic visits.  Prescriptions for parenteral nutrition, standard intravenous 
fluid and oxygen therapy were excluded since they are not considered as prescribed medicines by the 
US FDA [38].  
 
The primary information abstracted from the case files was the chronic health conditions of the 
patients and associated comorbidities, the medicines prescribed for the co-existing comorbidities and 
for controlling acute state of the chronic illnesses, age, gender, dosage and route of administration. All 
the medicines prescribed were classified as anti-infectives (AIF), central nervous system (CNS) 
medicines, cardiovascular (CVS) medicines, steroids (STRs), analgesics (ANGs), and miscellaneous 
(MIS) as previously reported in a systematic review of drug utilization studies [39].  
 
Off-label prescribing was identified and categorised according to the definition of Saiyed et al [11], i.e. 
medicines not licensed for specific paediatric age-groups, unavailable in paediatric formulations, 
prescribed for different indications to the one registered, with dose or dosing regimen different from 
recommendations, or prescribed for use via a different route from the recommendations. The 
reference sources for determining approved or licensed indications were the British National 
Formulary for children, BNFc [40] and the American Hospital Formulary Service, AHFS, Drug 
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information, 2015 [41]. Both are considered authoritative sources. However, discrepancies between 
both sources were resolved using the Pediatric and Neonatal Dosage Handbook [42]. 
 
2.3. Ethical consideration 
Approval was sought and received from the Health Research and Ethics Committee of LUTH, Nigeria. 
 
2.4 Statistical analysis 
The prevalence of off-label prescribing was determined as the proportion of off-label medicines to all 
oral medicines prescribed and expressed as a percentage. The pattern of off-label prescribing 
according to medicine group was also described and expressed as a percentage. The association 
between off-label prescribed medicines and age, gender, chronic condition, and medicine group was 
determined.  
 
Statistical analyses were performed with SPSS version 17. Data were presented as simple descriptive 
statistics and the association between the category of off-label prescription and age-group of the 
patients, gender, chronic condition or class of medicines prescribed was determined with Pearson 
Chi-VTXDUHWHVWRI)LVFKHU¶VH[DFWZKHUHDSSURSULDWH A value of p <0.05 is considered to be 
statistically significant. 
 
3. Results 
A total of 477 patients were included in the study. 43 (9%) had asthma, 172 (36.1%) had sickle cell 
anaemia, and 262 (54.9%) had epilepsy. The majority of the patients were 2-11 years old (1317; 
75.4%).  There were more males (273; 57.2%) than females (204; 42.8%) in this study. The median 
[Interquartile range (IQR)] of their age was 4 (0.06- 16) years. There were a total of 1746 
prescriptions. Children (347; 72.8.0%) and infants and toddlers (28; 13.5%) predominated and 
received, respectively, 1317 (75.5%) and 208 (11.9%) prescriptions.  The proportion of prescriptions 
received per disease group were:  asthma (155; 8.9%), sickle cell anaemia (626; 35.9%), and 
epilepsy (965; 55.2%).  
 
Out of 1746 prescribed medicines, 135 (7.7%) were identified as off-label. The class and specific off-
label medicines prescribed for the patients, as well as the categories of off-label prescribing, are 
presented in Table 1.  
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Table 1: Specific medicines prescribed in off-label manner for dose, indication, and age in a sample of 
children (477) with asthma, epilepsy and sickle cell anaemia seen at the LUTH (January to October, 
2015) 
Specific off-label medicine 
prescribed 
Proportion of 
the medicine 
prescribed      
n (%) 
Category of off-label prescription based on 
inappropriateness of the following: 
Dose 
n= 93 
Indication 
n= 23 
Age 
n= 19 
 Nervous system medicines              50 (37.0)             44 (47.3)            3 (13.0)         3 (15.8) 
Carbamazepine 19 (14.1) 18 1 - 
Sodium valproate 9 (6.7) 8 - 1 
Clonazepam 5 (3.7) 3 - 2 
Phenobarbitone 4 (2.9) 4 - - 
Diazepam 3 (2.2) 3 - - 
Reserpine 3 (2.2) 2 1  
Methylphenidate 
 
2 (1.5) 2 - 
 
- 
Pyridostigmine bromide 2 (1.5) 2 - - 
Atropine 2 (1.5) 2 - - 
Levetiracetam 1 (0.7) - 1 - 
Anti-infective Medicines                   36 (26.7)             24 (25.8)        7 (30.4)          5 (26.3) 
Cefotaxime 8 (5.9) 7 - 1 
Cefuroxime 6 (4.4) 6 - - 
Chloramphenicol 4 (2.9) - - 4 
Cefriaxone 3 (2.2) 2 1 - 
Quinine 3 (2.2) 1 2 - 
Cloxacillin 2 (1.5) 1 1 - 
Clotrimazole 2 (1.5) 2 - - 
Flucoxacillin 2 (1.5) - 2 - 
Amoxixillin/clavunalate 2 (1.5) 2 - - 
Metronidazole 1 (0.7) - 1 - 
Meropenem 1 (0.7) 1 - - 
Proguanil 1 (0.7) 1 - - 
Amikacin 1 (0.7) 1 - - 
           Miscellaneous                          18 (13.3)               8 (8.6)         4 (17.4)         6 (31.6) 
Ranitidine 8 (5.9) 5 2 1 
Sildenafil 5 (3.7) - - 5 
ketotifen 4 (2.9) 3 1 - 
Loratidine 1 (0.7) - 1 - 
            Analgesics                                12 (8.9)                   9 (9.7)                -           3 
(15.8) Pentazocine 3 (2.2) 3 - - 
Diclofenac 3 (2.2) 1 - 2 
Dipyrone 2 (1.5) 2 - - 
Ketoprofen 1 (0.7) 1 - - 
Codeine 1 (0.7) - - 1 
Aspirin 1 (0.7) 1 - - 
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Note: 
NB: 
)LVFKHU¶VH[DFW test, p< 0.001; there is a statistically significant association between the drug classes and the 
categories of off-label prescription. 
 
Nervous system medicines (50; 37.0%) were the most prescribed, followed by anti-infective agents 
(36; 26.4%), and miscellaneous medicines (18; 13.3%). Carbamazepine was the medicine most 
frequently prescribed in an off-label manner, followed by sodium valproate, cefotaxime and ranitidine 
(Table 1). Off-label prescribing were for dose (93; 68.9%), indication (22; 16.3%), and age (20; 
14.8%). None of the patients was exposed to off-label prescription related to the formulation.  There 
was a statistically significant association between the class and category of medicines prescribed in 
off-label manner for all the patients (p< 0.001).  
 
The categories of off-label prescriptions for the patients according to their age-group are presented in 
Table 2. Off-label prescribing was most common among infants and toddlers, and children (Table 2).  
However, there was no statistically significant association between the category of off-label 
prescription and age groups (p= 0.624).  
 
Table 2 Exposure to various categories of off-label prescriptions according to the age group   
 
 
 
 
 
1RWH)LVFKHU¶VH[DFWWHVWS QRVWDWLVWLFDOO\significant difference between age group of the patients and 
the categories of off-label prescription. 
 
Table 3 illustrates the category of off-label prescriptions compared with the gender of patients. 
Although, exposure to medicines prescribed in an off-label manner occurred more in females than 
males, this was not statistically significant (p= 0.068).  
 
Ibuprofen 1 (0.7) 1 - - 
Steriods   12 (8.9)                7 (7.5) 5 (21.7) - 
Prednisolone 5 (3.7) 4 1 - 
Hydrocortisone 3 (2.2) 1 2 - 
Budesonide 2 (1.5) 2 - - 
Dexamethasone 2 (1.5) - 2 - 
       Cardiovascular medicines            7 (5.2)             1 (1.1)         3 (13.0)          3 (15.8) 
Furosemide 4 (2.9) 1 3 - 
Lisinopril 2 (1.5) - - 2 
Digoxin 1 (0.7) - - 1 
Total 135(100.0) 93(68.9%) 22(16.3%) 20(14.8%) 
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Table 3: Gender and category of off-label medicine prescribed 
 
 
NB: Pearson Chi square test, p= 0.068; there is no statistically significant association between gender of the 
patients and the categories of off-label prescription. 
 
The type of illness was compared with the category of off-label prescriptions (Table 4). Exposure to 
medicines prescribed in an off-label manner was highest among children with asthma, followed by 
epilepsy and finally sickle cell disease. There was no statistically significant association between the 
illness type and the category of off-label medicine prescribed (p= 0.925).  
 
Table 4: Type of illness and category of off-label medicine prescribed 
 
 
NB: )LVFKHU¶VH[DFWWHVWS-value= 0.925; no statistically significant association between age group of the patients 
and the categories of off-label prescription. 
 
4. Discussion 
 
Altogether, the rate of prescribing for off-label use of medicines for children with epilepsy, asthma and 
sickle cell anaemia was 7.7%.  The 9.7% rate of prescribing medicine for an off-label use observed in 
children with epilepsy was substantially lower than 53% reported among children with 
pharmacoresistant epilepsy prescribed off-label antiepileptic medicines in Italy [33]. Similarly, the rate 
(10.3%) for children with asthma (Table 4) was lower than 29.8% reported for respiratory medicines 
prescribed for off-label use among a general paediatric population in Germany [43]. It was also lower 
than 34.5% reported for off-label use of anti-allergic medicines prescribed for pre-school children with 
allergic diseases in Portugal [35].  Consequently overall, the extent of off-label prescribing for each of 
the three chronic paediatric diseases studied was lower than reported for similar studies. Caution is 
however required when comparing our data with other studies because many of the medicines 
approved for the treatment of epilepsy in for instance Italy and those approved for the treatment of 
asthma in for instance Germany are not included in the national essential medicines list in Nigeria 
[28]. Consequently, we may well have underestimated the rate of off-label medicine use with regards 
to anti-epileptic and anti-asthmatic medicines.  
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Many factors may have also contributed to these wide variations. Most important are differences in 
the population and the age groups, the methodology used, the pattern of medicines prescribed, the 
health conditions and sample sizes. We evaluated the prescriptions for three distinct chronic health 
conditions which contain medicines used specifically to treat each health condition as well as those 
used for concomitant comorbidities. In contrast, only pulmonary medicines for pulmonary conditions, 
i.e. inhaled bronchodilators, inhaled and oral corticosteroids, mast cell stabilizers, leukotrienes, and 
xanthines, were evaluated in the German study [43]. Anti-allergic medicines comprising inhaled 
FRUWLFRVWHURLGVQDVDODQGWRSLFDOFRUWLFRVWHURLGVORQJDFWLQJȕ2 agonists, oral antihistamines, and 
topical immunomodulators were the medicines evaluated in the off-label prescriptions for allergic 
diseases among pre-school children in Portugal [35]. By contrast, the majority of the medicines 
evaluated in the German and Polish studies were not prescribed for asthmatic patients in our study. In 
the Italian study, only antiepileptic drugs including clobazam, lamotrigine, vigabatrin, ethosuximide, 
and levetiracetam were evaluated [33]. Of the 27 medicines evaluated, the five earlier antiepileptic 
medicines were the most frequently used in an off-label manner for indication or age. By contrast, 
only six antiepileptic medicines were evaluated in our study and no patient was treated for pharmaco-
resistant epilepsy. 
 
Furthermore, while these studies have defined off-label medicines in relation to deviation from 
recommended ages, indications and doses [33, 35, 43], we included non-recommended formulations 
and routes of administration in our definition of off-label prescription. This may be one reason why 
only a small number of off-label prescriptions were received by the patients in our study. Our sample 
size was also small compared with other studies [33, 43]; however, comparable to pre-school children 
studied by Morais-Almeida and Cabral [35]. Other reasons for the differences seen may include the 
fact that this study was undertaken in a tertiary referral centre involving trained paediatricians who 
supervise the prescribing of young physicians undergoing postgraduate training. However, this is 
important as these physicians may well go on to treat children in other settings once trained. 
 
The off-label medicine exposures in this study were related to dosage (68.9%), clinical indication 
(16.3%), or age (14.8%) (Tables 1- 4). Similar categories have been reported with anti-allergic drugs 
in allergic pre-school children in Portugal [29]. However, exposures to off-label use of medicines 
related to only age, dose, or both have been evaluated in other studies involving children with 
epilepsy and chronic respiratory problems [33, 43]. The lack of an acceptable uniform definition and 
categorisation of off-label use of medicine in drug utilisation studies will continue to generate 
discrepancies in study results unless addressed. Unlike our study where off-label prescribing outside 
the recommended dosage predominates, off-label prescribing relating to age or clinical indication was 
the major finding in other studies [33, 43].  
 
Nervous system and anti-infective medicines were the two major classes of medicines prescribed in 
an off-label manner (Table 1). These classes, as well as cardiovascular medicines, are among those 
well studied in paediatric randomised clinical trials with documented safety outcomes in children [44]. 
While our results suggest a low rate of off-label prescribing, the proportion of off-label prescribing for 
term newborn infants, infants, and toddlers (18.0%), as well as those relating to dose (68.9%), 
suggests a need for improvement especially given the risk of dose-related under-treatment or adverse 
drug toxicity in this group of patients. Newborn infants, infants, and toddlers are rarely included in 
randomised clinical trials [44] and evidence-based safety information regarding off-label prescribing of 
medicines may not be available. We will be looking to explore this further in future research to 
improve prescribing for these patients. 
  
Among the three clinical conditions evaluated in this study, off-label prescribing for children with 
epilepsy was 9.7%. This may reflect the high number of children with epilepsy and the high overall 
number of prescriptions they received in this study. However, there was no significant association 
between the illness type and the category of off-label prescription.  This suggests that off-label 
prescribing relating to dosage, clinical indication or age may not vary significantly among chronically ill 
children in similar circumstances.  We will again be looking at this further to see if prescribing can be 
improved in this group of patients. 
 
A limitation of our study is that the prescriptions were audited retrospectively. Consequently, we can 
only draw conclusions about off-label prescriptions but not about the actual use of off-label medicines.  
In addition, being a retrospective study, we were unable to gather data on the consequences of the 
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off-label use of medicines and the actions taken by the physicians to address any resulting problem. 
Medication history documented in the case files may also be incomplete and cannot be corroborated 
from patients. However, this reflects current clinical practice across countries. We also could not 
analyse specific indications for all prescriptions since clinical and medication histories are often 
incompletely documented [45].  Consequently, it was impossible to know if the prescriptions were 
based on appropriate risk-benefit consideration. Finally, we also confined our study to a single tertiary 
referral centre. However, even in this situation where typically patients may be referred from other 
hospitals, there was a relatively low rate of off-label prescribing. This was a surprise given the findings 
from other studies, although welcomed. Overall though, we believe our findings are robust and 
provide direction for the future. However, further analyses are planned to assess the extent of off-
label prescribing across Nigeria to see whether specific interventions are needed to maintain the low 
rates of off-label prescribing seen in this population. 
 
5. Conclusion 
The rate of off-label prescribing for children with epilepsy, asthma and sickle cell was low in this study, 
with off-label prescriptions outside approvals for dosage and age the most frequently encountered. 
Nervous system and anti-infective medicines were the two main classes of off-label medicines 
prescribed. Off-label prescribing should be guided by risk-benefit ratios and dosing guidelines to 
ensure safety is maximised. These will be the subject of future educational and other activities among 
paediatricians in Nigeria to reduce still further any adverse effects of off-label prescribing. 
 
Key points 
 
x Numerous medicines are used to treat concomitant and chronic illnesses in children. These 
medicines are often prescribed off-label. Previous studies evaluating off-label prescribing for 
children with chronic illnesses have typically been performed in developed countries and excluded 
medicines used for concomitant illnesses 
x Epilepsy, asthma and sickle cell anemia are among the chronic conditions posing a significant 
economic burden on parents in Nigeria; consequently, important to study the off-label use of 
medicines to treat these conditions in Nigeria 
x Overall, these three conditions were associated with a low level of off-label prescriptions, which is 
encouraging 
x Central nervous system and anti-infective agents were the two classes of medicines prescribed 
for children with epilepsy, asthma and sickle cell anemia. Their off-label prescribing was mostly 
related to dose, indication, and age. 
x There appears to be no significant association between different categories of off-label 
prescribing and the three chronic conditions evaluated in this study 
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